Vegh Zsuzsanna, Kurti Zsuzsanna, Lakatos Peter L
First Department of Medicine, Semmelweis University, Budapest, Hungary.
Dig Dis. 2017;35(1-2):101-106. doi: 10.1159/000449089. Epub 2017 Feb 1.
Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts.
最近，生物类似药英夫利昔单抗（IFX）在一些欧洲和非欧洲国家用于治疗炎症性肠病已变得普遍。来自真实队列的疗效、安全性和免疫原性数据正在积累。首批报告显示，在诱导和维持缓解、黏膜愈合、安全性和免疫原性方面，其结果与原研IFX相似。在本综述中，我们旨在总结真实队列报告的关于生物类似药IFX的疗效、安全性和免疫原性的现有知识。
